4DMedical Strengthens Balance Sheet to Accelerate U.S. Growth
4DMedical Limited (ASX: 4DX) is an innovative global medtech firm dedicated to revolutionizing respiratory healthcare by leveraging cutting-edge imaging technology and artificial intelligence. The company recently completed a AU$150 million institutional placement at AU$3.80 per share, attracting strong demand from new global long-only investors alongside existing shareholders. Proceeds will primarily support the accelerated commercial rollout of its flagship CT:VQ™ product in the United States, following rapid adoption at leading academic medical centres such as Stanford, Cleveland Clinic, and UC San Diego after FDA clearance. The capital raise limits dilution to below 4% and results in a pro forma cash balance exceeding AU$200 million, providing funding visibility through to profitability. CT:VQ™, alongside 4DMedical’s broader XV Technology® software portfolio, is delivered via a scalable SaaS model that integrates seamlessly into hospital workflows. With strategic partnerships, growing clinical validation, and strengthened financial capacity, 4DMedical is well positioned to establish a new standard in pulmonary imaging and expand its global footprint.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au
x
Daily Dose of Buy, Sell & Hold recommendations before the market opens.
Start Your 7 Days Free Trial Now!
We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to this. Read our Privacy Policy and Terms & Conditions
4DMedical Strengthens Balance Sheet to Accelerate U.S. Growth
4DMedical Limited (ASX: 4DX) is an innovative global medtech firm dedicated to revolutionizing respiratory healthcare by leveraging cutting-edge imaging technology and artificial intelligence. The company recently completed a AU$150 million institutional placement at AU$3.80 per share, attracting strong demand from new global long-only investors alongside existing shareholders. Proceeds will primarily support the accelerated commercial rollout of its flagship CT:VQ™ product in the United States, following rapid adoption at leading academic medical centres such as Stanford, Cleveland Clinic, and UC San Diego after FDA clearance. The capital raise limits dilution to below 4% and results in a pro forma cash balance exceeding AU$200 million, providing funding visibility through to profitability. CT:VQ™, alongside 4DMedical’s broader XV Technology® software portfolio, is delivered via a scalable SaaS model that integrates seamlessly into hospital workflows. With strategic partnerships, growing clinical validation, and strengthened financial capacity, 4DMedical is well positioned to establish a new standard in pulmonary imaging and expand its global footprint.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au